IDH inhibition in gliomas: from preclinical models to clinical trials
Top Cited Papers
- 17 May 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (7) , 395-407
Abstract
Gliomas are the most common malignant primary brain tumours in adults and cannot usually be cured with standard cancer treatments. Gliomas show intratumoural and intertumoural heterogeneity at the histological and molecular levels, and they frequently contain mutations in the isocitrate dehydrogenase 1 (IDH1) or IDH2 gene. IDH-mutant adult-type diffuse gliomas are subdivided into grade 2, 3 or 4 IDH-mutant astrocytomas and grade 2 or 3 IDH-mutant, 1p19q-codeleted oligodendrogliomas. The product of the mutated IDH genes, d-2-hydroxyglutarate (D-2-HG), induces global DNA hypermethylation and interferes with immunity, leading to stimulation of tumour growth. Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to reduce D-2-HG levels and induce cellular differentiation in preclinical models and to induce MRI-detectable responses in early clinical trials. The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery. In this Review, we describe the pathway of development of IDH inhibitors in IDH-mutant low-grade gliomas from preclinical models to clinical trials. We discuss the practice-changing implications of the INDIGO trial and consider new avenues of investigation in the field of IDH-mutant gliomas.Keywords
This publication has 174 references indexed in Scilit:
- Noninvasive detection of brain gliomas using plasma cell‐free DNA 5‐hydroxymethylcytosine sequencingInternational Journal of Cancer, 2022
- Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivoActa Neuropathologica, 2017
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- What do we know about IDH1/2 mutations so far, and how do we use it?Acta Neuropathologica, 2013
- Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsActa Neuropathologica, 2012
- CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomasActa Neuropathologica, 2012
- Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancersThe Journal of Pathology, 2011
- Monoclonal antibody specific for IDH1 R132H mutationActa Neuropathologica, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Continuous growth of mean tumor diameter in a subset of grade II gliomasAnnals of Neurology, 2003